{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-015517","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.102352+00:00","generated_at":"2026-05-22T04:36:20.953213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set","bullets":["GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.","Cash and equivalents $119.3M as of March 31, 2025, down from $118.0M at Dec 31, 2024.","Costs and expenses $18.0M, up $7.4M YoY, driven by stock-based comp and organization expansion.","On track to launch nsPFA Percutaneous Electrode System in H2 2025; U.S. IDE for cardiac surgery and catheter systems expected mid-2025.","Treated 100 patients in Europe with nsPFA 360° catheter; data presented at HRS 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-015517","json":"https://secwatch.observer/filing/0001437749-25-015517.json","markdown":"https://secwatch.observer/filing/0001437749-25-015517.md","text":"https://secwatch.observer/filing/0001437749-25-015517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/0001437749-25-015517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/plse20250506_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:36:20.953213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}